BYSI
Price
$1.59
Change
+$0.04 (+2.58%)
Updated
Dec 20, 04:59 PM (EDT)
RCUS
Price
$15.52
Change
+$0.06 (+0.39%)
Updated
Dec 20, 04:59 PM (EDT)
58 days until earnings call
Ad is loading...

BYSI vs RCUS

Header iconBYSI vs RCUS Comparison
Open Charts BYSI vs RCUSBanner chart's image
BeyondSpring
Price$1.59
Change+$0.04 (+2.58%)
Volume$242
CapitalizationN/A
Arcus Biosciences
Price$15.52
Change+$0.06 (+0.39%)
Volume$7.66K
CapitalizationN/A
BYSI vs RCUS Comparison Chart
Loading...
BYSI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BYSI vs. RCUS commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BYSI is a Hold and RCUS is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (BYSI: $1.59 vs. RCUS: $15.50)
Brand notoriety: BYSI and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BYSI: 246% vs. RCUS: 248%
Market capitalization -- BYSI: $63.27M vs. RCUS: $1.42B
BYSI [@Biotechnology] is valued at $63.27M. RCUS’s [@Biotechnology] market capitalization is $1.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BYSI’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • BYSI’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both BYSI and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BYSI’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 4 bullish TA indicator(s).

  • BYSI’s TA Score: 5 bullish, 3 bearish.
  • RCUS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BYSI is a better buy in the short-term than RCUS.

Price Growth

BYSI (@Biotechnology) experienced а -3.05% price change this week, while RCUS (@Biotechnology) price change was -3.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

BYSI is expected to report earnings on Nov 27, 2024.

RCUS is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.42B) has a higher market cap than BYSI($63.3M). BYSI YTD gains are higher at: 76.667 vs. RCUS (-18.848). BYSI has higher annual earnings (EBITDA): -15.78M vs. RCUS (-257M). RCUS has more cash in the bank: 1.09B vs. BYSI (14.4M). BYSI has less debt than RCUS: BYSI (3.69M) vs RCUS (58M). RCUS has higher revenues than BYSI: RCUS (263M) vs BYSI (1.88M).
BYSIRCUSBYSI / RCUS
Capitalization63.3M1.42B4%
EBITDA-15.78M-257M6%
Gain YTD76.667-18.848-407%
P/E RatioN/AN/A-
Revenue1.88M263M1%
Total Cash14.4M1.09B1%
Total Debt3.69M58M6%
FUNDAMENTALS RATINGS
BYSI vs RCUS: Fundamental Ratings
BYSI
RCUS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6156
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (58) in the Pharmaceuticals Major industry is in the same range as BYSI (61). This means that RCUS’s stock grew similarly to BYSI’s over the last 12 months.

RCUS's Profit vs Risk Rating (75) in the Pharmaceuticals Major industry is in the same range as BYSI (100). This means that RCUS’s stock grew similarly to BYSI’s over the last 12 months.

RCUS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as BYSI (98). This means that RCUS’s stock grew similarly to BYSI’s over the last 12 months.

RCUS's Price Growth Rating (56) in the Pharmaceuticals Major industry is in the same range as BYSI (61). This means that RCUS’s stock grew similarly to BYSI’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as BYSI (100). This means that RCUS’s stock grew similarly to BYSI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BYSIRCUS
RSI
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Aroon
ODDS (%)
Bearish Trend 4 days ago
86%
N/A
View a ticker or compare two or three
Ad is loading...
BYSI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LFMD5.040.14
+2.86%
LifeMD
VTMX25.960.69
+2.73%
Corporacion Inmobiliaria Vesta SAB de CV
CVS44.360.58
+1.32%
CVS HEALTH Corp
UPWK16.440.20
+1.23%
Upwork
SRTS7.10-0.11
-1.53%
Sensus Healthcare

BYSI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BYSI has been loosely correlated with GOSS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BYSI jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BYSI
1D Price
Change %
BYSI100%
+2.58%
GOSS - BYSI
38%
Loosely correlated
-0.11%
CYTK - BYSI
37%
Loosely correlated
+4.56%
VNDA - BYSI
33%
Poorly correlated
+3.24%
RCUS - BYSI
31%
Poorly correlated
+0.26%
APGE - BYSI
30%
Poorly correlated
+1.47%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ACLX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+0.26%
ACLX - RCUS
46%
Loosely correlated
+0.44%
OCUL - RCUS
46%
Loosely correlated
+0.59%
CRSP - RCUS
44%
Loosely correlated
+0.83%
PRME - RCUS
44%
Loosely correlated
+3.94%
DNLI - RCUS
44%
Loosely correlated
-0.19%
More